BioLineRx (BLRX) Enterprise Value (2023 - 2025)
Historic Enterprise Value for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$25.2 million.
- BioLineRx's Enterprise Value rose 1357.76% to -$25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.2 million, marking a year-over-year increase of 1357.76%. This contributed to the annual value of -$19.6 million for FY2024, which is 5450.06% up from last year.
- As of Q3 2025, BioLineRx's Enterprise Value stood at -$25.2 million, which was up 1357.76% from -$28.2 million recorded in Q2 2025.
- Over the past 5 years, BioLineRx's Enterprise Value peaked at -$19.6 million during Q4 2024, and registered a low of -$43.3 million during Q1 2023.
- In the last 3 years, BioLineRx's Enterprise Value had a median value of -$28.2 million in 2024 and averaged -$30.6 million.
- The largest annual percentage gain for BioLineRx's Enterprise Value in the last 5 years was 5450.06% (2024), contrasted with its biggest fall of 1234.21% (2024).
- Over the past 3 years, BioLineRx's Enterprise Value (Quarter) stood at -$43.0 million in 2023, then skyrocketed by 54.5% to -$19.6 million in 2024, then fell by 28.88% to -$25.2 million in 2025.
- Its last three reported values are -$25.2 million in Q3 2025, -$28.2 million for Q2 2025, and -$26.4 million during Q1 2025.